Compare VOC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOC | IMMP |
|---|---|---|
| Founded | 2010 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 58.2M |
| IPO Year | N/A | 2012 |
| Metric | VOC | IMMP |
|---|---|---|
| Price | $3.30 | $0.46 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 106.7K | ★ 22.8M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 12.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.60 | $0.29 |
| 52 Week High | $3.84 | $3.53 |
| Indicator | VOC | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 33.45 |
| Support Level | $3.24 | $0.29 |
| Resistance Level | $3.31 | $1.81 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 35.42 | 5.54 |
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.